Pfizer attacks Novartis on biogenerics

New information about Novartis AG's efforts to persuade U.S. and EU regulators to approve a generic form of recombinant human growth hormone came to light last week as a result of Pfizer Inc.'s effort to shoot down the application.

PFE (New York, N.Y.) filed a Citizen Petition requesting that FDA "immediately deny approval" of an NDA filed for Omnitrop somatropin by Novartis subsidiaries Biochemie U.S. Inc. and Sandoz Inc...